I2032
Monoclonal Anti-Insulin-Like Growth Factor Binding Protein-1 antibody produced in mouse
clone 33627.11, purified immunoglobulin, lyophilized powder
Synonyme(s) :
Anti-IGFBP-1
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Produits recommandés
Source biologique
mouse
Niveau de qualité
Conjugué
unconjugated
Forme d'anticorps
purified immunoglobulin
Type de produit anticorps
primary antibodies
Clone
33627.11, monoclonal
Forme
lyophilized powder
Espèces réactives
human
Technique(s)
capture ELISA: suitable
neutralization: suitable
western blot: 1-2 μg/mL
Isotype
IgG1
Numéro d'accès UniProt
Température de stockage
−20°C
Modification post-traductionnelle de la cible
unmodified
Informations sur le gène
human ... IGFBP1(3484)
Description générale
The effects of insulin-like growth factors (IGF) are modulated by a family of insulin-like growth factor binding proteins 1-6. (IGFBPs -1-6). IGFBP-1 is secreted as an endocrine factor by liver, kidneys, decidua and in human amniotic fluid, but has the ability to signal in autocrine and paracrine fashion. Post-translational modifications such as ubiquitination, glycosylation and phosphorylation alter the activity of IGFBPs. Phosphorylation of IGFBP-1 is mainly mediated by Casein kinase I and II and cAMP-dependent protein kinases. IGFBP-1 alters the bioavailability of IGF in the serum by binding and sequestration so that a regulated amount id available to act on the target cells. The functions of IGFBP-1 are most important in the physiology of female reproductive system in mammals, for growth and development of the developing fetus
Monoclonal Anti-Human Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) recognizes recombinant human IGFBP-1. No cross-reactivity is seen with recombinant human IGFBP-2, IGFBP-3, and IGFBP-4.
Monoclonal Anti-Human Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) recognizes recombinant human IGFBP-1. No cross-reactivity is seen with recombinant human IGFBP-2, IGFBP-3, and IGFBP-4.
Spécificité
The biological activity is measured by its ability to neutralize recombinant human IGFBP-1 in the presence of recombinant human IGF-I.
Immunogène
purified recombinant human insulin-like growth factor binding protein 1, expressed in E. coli.
Application
Anti- Insulin-Like Growth Factor Binding Protein-1 antibody may be used for immunoblotting at a working concentration of 1-2 μg/ml. For ELISA, a working concentration of 2 μg/ml may be used. The antibody is suitable for neutralization reactions (ND50 is 10-40 μg/ml).
Forme physique
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline.
Clause de non-responsabilité
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Vous ne trouvez pas le bon produit ?
Essayez notre Outil de sélection de produits.
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Équipement de protection individuelle
Eyeshields, Gloves, type N95 (US)
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Terry J Smith
Pharmacological reviews, 62(2), 199-236 (2010-04-16)
This topically limited review explores the relationship between the immune system and insulin-like growth factors (IGF-I and IGF-II) and the proteins through which they act, including IGF-I receptor (IGF-IR) and the IGF-I binding proteins. The IGF/IGF-IR pathway plays important and
D J Fowler et al.
Human reproduction update, 6(5), 495-504 (2000-10-25)
Insulin-like growth factor-1 (IGFBP-1) is particularly important in human female reproductive physiology, where it is involved with other factors in a complex system which regulates menstrual cycles, puberty, ovulation, decidualization, implantation and fetal growth. This has implications for clinical obstetrics
K M Kelley et al.
The international journal of biochemistry & cell biology, 28(6), 619-637 (1996-06-01)
The IGFBPs are a family of homologous proteins that have co-evolved with the IGFs and that confer upon the IGF regulatory system both functional and tissue specificity. IGFBPs are not merely carrier proteins for IGFs, but hold a central position
M Westwood
Reviews of reproduction, 4(3), 160-167 (1999-10-16)
Insulin-like growth factors and their binding proteins are key regulators of fetal and maternal tissue growth and development during human pregnancy. Insulin-like growth factors, particularly IGF-II, are produced in abundance by the trophoblast cells of the placenta, whereas one of
Ali Vaziri-Gohar et al.
Molecular and cellular endocrinology, 422, 160-171 (2015-12-23)
Tamoxifen, a selective estrogen receptor modulator, is a commonly prescribed adjuvant therapy for estrogen receptor-α (ERα)-positive breast cancer patients. To determine if extracellular factors contribute to the modulation of IGF-1 signaling after tamoxifen treatment, MCF-7 cells were treated with IGF-1 in
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique